The Quietmind Foundation (QMF) - Baylor Scott & White Research Institute (BSWRI), published trial confirmed that self-administered, brief, 1070nm light stimulation improved both cognitive, motor and mood symptoms associated with early to mid-stage Alzheimer's and Parkinson's disease. QMF now is providing a 12-24 month. single-subject program combining 1070 transcranial and intranasal photobiomodulation with neurofeedback training.
The program fee includes all equipment, quarterly qEEG and neuropsychological assessments, monthly photobiomodulation and neurofeedback training program monitoring and protocol revision. All services are provided remotely at the subject's home excluding qEEG assessments.
All inclusive participant fee: $10,000 (12 months) and $18,000 (24 months).
Contact Dr. Berman for details at [email protected]
Click the link below to review the Baylor Scott & White Photobiomodulation clinical trial.
The program fee includes all equipment, quarterly qEEG and neuropsychological assessments, monthly photobiomodulation and neurofeedback training program monitoring and protocol revision. All services are provided remotely at the subject's home excluding qEEG assessments.
All inclusive participant fee: $10,000 (12 months) and $18,000 (24 months).
Contact Dr. Berman for details at [email protected]
Click the link below to review the Baylor Scott & White Photobiomodulation clinical trial.

1transcranial_near_infrared_light_stimulations_improve_cognition_in_patients_with_dementia.pdf | |
File Size: | 470 kb |
File Type: |
Randomized Double-Blind Placebo-Controlled Clinical Trial
In cooperation with Texas A&M University's Dept. of Neurosurgery, Quietmind Foundation enrolled 100* subjects age 50-85 years experiencing memory problems and who had been independently diagnosed with early to mid-stage dementia to participate in this trial. The study used low-level infrared light stimulation directed to the head. The stimulation sessions were conducted at home, twice daily, for 6 minutes over 60 consecutive days. The trial was randomized, placebo controlled and double blinded. Trial Procedure: Individuals that matched the clinical trial eligibility criteria went through two unique assessments at the start, mid-point, and ending of the trial period.
Participants repeated the EEG and cognitive assessments twice more during the two month trial. Results for the reported sample (N=69) were significantly positive. (Download publication above for details.) * Note: Results reported in the published paper are limited to the Texas cohort (N=69) and include only pre and post treatment neuropsychological testing results. Preparation of additional results including QEEG and additional subjects in the Philadelphia cohort are being developed. |